Outlook Therapeutics, Inc. (NASDAQ: OTLK)

This lawsuit is for anyone who acquired securities in Outlook Therapeutics, Inc. (NASDAQ: OTLK) from August 3, 2021 through August 29, 2023.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that it had controls in place to produce its wet age-related macular degeneration treatment, ONS-5010, safely despite lacking such controls.

On August 30, 2023, Outlook disclosed that the FDA had issued a complete response letter regarding the Company’s wet age-related macular degeneration (“wet AMD”) treatment, ONS-5010. The FDA concluded that “it could not approve the [biologics license application]” due to “several [chemistry manufacturing and controls] issues, open observations from pre-approval manufacturing inspections, and lack of substantial evidence.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Outlook Therapeutics, Inc. (NASDAQ: OTLK) from August 3, 2021 through August 29, 2023 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.